BridgeBio

BridgeBio Pharma is a biopharmaceutical company based in Palo Alto, California, founded in 2015. The company is dedicated to discovering, creating, testing, and delivering innovative medicines for patients with genetic diseases and cancers that have clear genetic factors. BridgeBio operates globally, with a presence in the U.S., Canada, France, Germany, Switzerland, and the UK. The company offers several therapies, including Acoramidis for transthyretin amyloidosis, NULIBRY for molybdenum cofactor deficiency, and TRUSELTIQ, a precision oncology therapy. BridgeBio's pipeline includes programs in precision cardiorenal, mendelian disorders, gene therapy, and oncology, focusing on conditions with significant unmet medical needs. Recently, BridgeBio secured up to $1.25 billion in capital to enhance the development and commercialization of its genetic medicines, reflecting its commitment to translating scientific advances into clinical solutions efficiently.